Liquidia Corp
Q2 2026 Earnings
Market Reaction
Did LQDA Beat Earnings? Q2 2026 Results
Liquidia Corporation delivered a mixed second quarter for 2026, posting revenue of $171.68 million, a 1.90% beat against the $168.48 million consensus and a staggering 1,842.7% increase from the year-ago period, while GAAP earnings per share of $0.74 fell short of the $0.84 analyst estimate by 11.48%, as surging commercial and pipeline investment costs weighed on the bottom line. The story behind both figures is the same: YUTREPIA, Liquidia's inhaled dry-powder treprostinil, continued its rapid commercial ramp, with net product sales reaching $170.38 million, up 31% sequentially from Q1 2026, driven by a prescriber base exceeding 1,100 physicians and over 5,000 patients started on therapy since launch. The company swung to GAAP net income of $74.72 million from a net loss of $41.58 million a year ago, and its cash position grew to $284.18 million, supporting a self-funded pipeline of 10 clinical studies. With an annualized net product sales run-rate exiting the quarter at approximately $682 million and key programs including the global pivotal Re-Spire study now recruiting, institutional investors holding roughly 65% of shares appear positioned for the next phase of growth.
- YUTREPIA net product sales of $170.4 million in Q2 2026, up 31% sequentially from Q1 2026
- Approximately 5,900 unique patient prescriptions since launch in June 2025
- More than 5,000 patients started on treatment since launch
- Prescription-to-start conversion rate remained strong above 85%
- Over 1,100 prescribers, with more than 30% prescribing to at least 5 patients
- Inhaled prostacyclin category has grown almost 40% since YUTREPIA launch
- Fourth consecutive quarter of increasing profitability
“We are pleased by the sustained adoption of YUTREPIA as the inhaled prostacyclin of choice. The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth. We are building on that momentum by strengthening the clinical evidence for YUTREPIA in PAH and PH-ILD patients transitioning from other therapies, and advancing studies in new indications that may broaden its impact. Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire, our pivotal study for L606, which we believe can raise that bar even further, beyond any therapy currently available or in development.”
Liquidia CEO, on the earnings call
Forward Guidance & Outlook
Liquidia exited Q2 2026 at an annualized net product sales run-rate of approximately $682 million. The company is progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil, including initiating enrollment in Re-Spire, the global pivotal study for L606 in PH-ILD. Additional studies planned for initiation include LTI-403 (selexipag transition to YUTREPIA, Q3 2026), SPRINT hemodynamic study (Q4 2026), RE-WARM for SSc-Raynaud's (Q4 2026), and programs in IPF/PPF and PH-COPD (planned for 2027). The company's growing cash position of $284.2 million supports self-funded investment in these pipeline programs.
LQDA YoY Financials
LQDA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.